A Cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five european countries

Applied Health Economics and Health Policy

Volumn 10, Issue 2, 2012, Pages 127-138

  Iannazzo, Sergio ^a   Carsi, Michela ^b   Chiroli, Silvia ^c  

^a IMS Consulting Group   (Italy)

^b AdRes HE and OR   (Italy)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET; PHOSPHATE BINDING AGENT; VITAMIN D;

ADULT; AGED; ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; COST UTILITY ANALYSIS; CZECH REPUBLIC; DIALYSIS; DRUG COST; EUROPE; FRACTURE; HEALTH ECONOMICS; HUMAN; ITALY; KIDNEY DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OPEN STUDY; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PORTUGAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY HYPERPARATHYROIDISM; SPAIN; SWITZERLAND; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CALCIMIMETIC AGENTS; COST-BENEFIT ANALYSIS; EUROPE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MARKOV CHAINS; MIDDLE AGED; NAPHTHALENES; QUALITY-ADJUSTED LIFE YEARS; YOUNG ADULT;

EID: 84857478502     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11597980-000000000-00000     Document Type: Article

References (54)

1. Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24 (5): 1506-23
2. Goldsmith D, Kothawala P, Chalian A, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of fracture and need for parathyroidectomy in CKD. Am J Kidney Dis 2009; 53 (6): 1002-13
3. Eknoyan G, Levin A, Levin N. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 Suppl. 3: S1-201
4. Kidney Disease: ImprovingGlobalOutcomes (KDIGO) CKDMBDWorkGroup. KDIGOclinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; (113): S1-130
5. Messa P, Macario F, Yaqoob M, et al. The OPTIMA Study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36-45
6. Eandi M, Pradelli L, Iannazzo S, et al. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics 2010; 28: 1041-54
7. Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005; 20: 2186-93 (Pubitemid 41510096)
8. Cunningham J, Urena P, Reichel H, et al. Long-term (5-year) efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end stage renal disease (CKD STAGE 5) [abstract]. XLII Congress of the ERA-EDTA; 2005 June 4-7; Istanbul, Turkey
9. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality and morbidity in maintenance haemodialysis. J Am Soc Nephrol 2004; 15: 2208-18 (Pubitemid 39031360)
10. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3 and 4 study. J Am Soc Nephrol 2005; 16: 1788-93 (Pubitemid 41716485)
11. Trespalacios FC, Taylor AJ, Agodoa LY, et al. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003; 41 (6): 1267-77 (Pubitemid 36637983)
12. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-66 (Pubitemid 44435190)
13. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of parathyroidectomy in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Hemodial Int 2007; 11 (1): 62-71 (Pubitemid 46128682)
14. Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66: 2010-6
15. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007; 11 (18): iii, xi-xiii, 1-167
16. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998; 44: 215-32 (Pubitemid 28345184)
17. Nichol G, Kaul P, Huszti E, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004; 141: 343-51
18. Martin AJ, Glasziou PP, Simes RJ. A cardiovascular extension of the Health Measurement Questionnaire. J Epidemiol Community Health 1999; 53: 548-57 (Pubitemid 29401830)
19. Nease RFJ, Kneeland T, O'Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina: implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA 1995; 273: 1185-90
20. Brazier JE, Green C, Kanis JA, Committee of Scientific Advisors International Osteoporosis Foundation. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporosis Int 2002; 13: 768-76 (Pubitemid 36336721)
21. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, editors. Economic evaluation in health care. New York: Oxford University Press, 2001: 172-214
22. ISTAT: Italian National Institute of Statistics. Italian population life tables geographical area: Italia-males and females-year: 2005 [online]. Available from URL: http://www.demo.istat.it/unitav/index.html?lingua=eng [Accessed 2010 Jul 01]
23. INE: Instituto Nacional de Estadística. Mortality tables for the population of Spain 1992-2005 [online]. Available from URL: http://www.ine.es/ jaxi/tabla.do?path=/t20/p319a/ 1992-2005/l1/&file=01001.px&type= pcaxis&L=1 [Accessed 2010May 01]
24. INE: Instituto Nacional de Estatística. Mortality table for Portugal, 2006-2008 [online]. Available from URL: http://www.ine.pt/xportal/ xmain?xpid=INE&xpgid=ine-base-dados&bdpagenumber=30&bdnivelgeo= 1&contexto=bd&bdtemas=1117&bdsubtemas=111714 [Accessed 2010 Mar 15]
25. Eurostat. Probability of dying by sex and age, 2008 [online]. Available from URL: http://epp.eurostat.ec.europa.eu/ portal/page/portal/population/data/ database [Accessed 2010 Jan 01]
26. SIN: Italian Society of Nephrology. Registro Italiano di Dialisi e Trapianto. Report 2005 [online]. Available from URL: http://www.sin-ridt.org/ sin-ridt.org.htm [Accessed 2008 Jun 01]
27. S.E.N: Sociedad Españ ola de Nefrología. Report of 2007. XXXVIII Congress of the Sociedad Españ ola de Nefrología; 2008 Oct 4-7; San Sebastían
28. S.P.N: Sociedade Portoguesa de Nefrologia. Gabinete de Registo, Relató rios Anuais 2008 [online]. Available from URL: http://www.spnefro.pt/ [Accessed 2009 Nov 01]
29. European Renal Association - European Dialysis and Transplant Association, ERA-EDTA. http://www.era-edta. org/ [Accessed 2009 Oct 01]
30. de Jager DJ, Grootendorst DC, Jager K J, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302: 1782-9
31. L'Informatore Farmaceutico. Italian directory of medicines and manufacturers. 69th Rev. Milan: Elsevier, 2009
32. Spanish Official Drug List. Catálogo de Especialidades Farmacéuticas. Consejo General de Colegios. Madrid: Oficiales de Farmacéuticos, 2007
33. CAPS: Catá logo de Aprovisionamento P-ublico da Sa-ude [online]. Available from URL: http://www.catalogo.minsaude. pt/ [Accessed 2009 Nov 01]
34. Federal Office of Public Health (FOPH). List of pharmaceutical specialties with effect from 01/03/2010 [online]. Available from URL: http://www.bag.admin.ch/themen/krankenversicherung/00263/00264/00265/index.html? lang=en [Accessed 2010 May 01]
35. SUKL(State Institute for Drug Control).Medicinal products database [online]. Available from URL: http://www.sukl.eu/modules/medication/search.php [Accessed 2009 Nov 20]
36. Nomenclatore Tariffario Nazionale: DRG tariffs. DMS 2006 Sep 12. Supplemento Ordinario alla Gazzetta Ufficiale 2006 Dec 13; 289
37. DRG 2006: Weight of DRG in the National Health System, All Patient version 23 [online]. Available from URL: http:// www.msc.es/estadEstudios/ estadisticas/inforRecopilaciones/anaDesarrolloGDR.htm [Accessed 2010 May 01]
38. DRG 2009: Portiaria N-839-A/2009, 31 July [online]. Available from URL: http://www.acss.min-saude.pt/Download sePublica%C3%A7%C3%B5es/TabelaseImpressos/ Pre% C3%A7osdoSNS/tabid/141/language/pt-PT/Default.aspx [Accessed 2009 Nov 01]
39. Swiss Federal Statistic Office, 2007. Statistics of economic data by case, classified by groups of patients AP-DRG and types of hospitals [online]. Available from URL: http:// www.bfs.admin.ch/bfs/portal/fr/index/themen/14/04/ 01/ data/01.html [Accessed 2010 May 01]
40. SDO. Statistiche sui ricoveri ospedalieri (Italian hospital discharge database) [online]. Available from URL: http://www.salute.gov.it/ ricoveriOspedalieri/ric-informazioni/ sceltafine.jsp?selcli=STG [Accessed 2009 Sep 01]
41. Spanish statistics on hospital admittance episodes classified by the DRG [online]. Available from URL: http:// www.msc.es/en/estadEstudios/estadisticas/ cmbd.htm [Accessed 2009 Oct 01]
42. Sistema de Classificação de Doentes em Grupos de Diagnósticos Homogéneos (GDH), Informação de Retorno, 2006 [online]. Available from URL: http://www.acss.minsaude.pt/Portals/0/ DownloadsPublicacoes/SNS/Info-Activid/Rel-Nacional-06.pdf [Accessed 2009 Nov 01]
43. Swiss Federal Statistic Office. Hospital medical statistics: number of case by age, classified by group of patients APDRG, 2008 [online]. Available from URL: http://www.bfs. admin.ch/bfs/portal/fr/index/themen/14/04/01/data/01. html [Accessed 2010May 01]
44. Institute of Health Information and Statistics of the Czech Republic (UZIS-IHIS CR). http://www.uzis.cz/en [Accessed 2009 Dec 01]
45. Bulková V, Fiala M, Chovančík J, et al. Analý za ná kladů na léčbu u pacientů s fibrilací síní v Č eské republice. Cor Vasa 2008; 50 (1): 23-7 (Pubitemid 351227910)
46. Ondráčková B, Barbora-Miklík R, Roman-Pařenica J, et al. Ná klady a délka hospitalizace u pacientů s akutním srdečním selhá ním. Farmakoekonomika 2007; 2 (2): 50-5
47. Ondráčková B, Barbora-Miklík R, Roman-Pařenica J, et al. Costs and length of stay in patients hospitalized for acute heart failure [abstract]. Value Health 2007; 10 (6): A418
48. Marie H, Pavel K, Libor S, et al. Management and cost of stroke in late nineties: Prague university hospital. Acta Clin Croat 2001; 40: 79-84
49. Cunningham J, Danese MD, Olson KA, et al. Effects of the calcimimetic cinacalcet HCI on cardiovascular disease, fracture, and health related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-800 (Pubitemid 43169924)
50. Eandi M, Giotta N, Santagostino Barbone G. Analisi costo/ efficacia di sevelamer nel trattamento dell'iperfosforemia del paziente in dialisi. Farmeconomia e Percorsi Terapeutici 2004; 5: 201-18
51. BOE - Boletín Oficial del Estado. Ministerio de Sanidad y Consumo. Resolution of March 1st, 2006, revising economic conditions applicable in 2006 to the healthcare services [online]. Available from URL: http://www.boe.es/ aeboe/consultas/bases-datos/doc.php?coleccion=iberlex&id=2006/04590 [Accessed 2009 Oct 01]
52. Sandoz MS, Ess SM, Keusch GW, et al. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001. Swiss Med Wkly. 2004; 134: 448-58 (Pubitemid 39221765)
53. Opatrný Jr K, Třeška V. Koncepce oboru nefrologie v Ceské republice. Aktuality v nefrologii 2001; 7: 118-26
54. WHO. CHOosing Interventions that are Cost Effective (WHO-CHOICE), 2000 [online]. Available from URL: http://www.who.int/choice [Accessed 2008 Dec 01]